MC4R rs17782313 基因多态性是否会影响运动诱导的脂肪氧化率?
Mert Sakar1, Cagri Dogan2, Necdet Apaydin3
1Ordu University, Ordu, Ordu, Turkey; mertsakar8@gmail.com.
概括
MC4R rs17782313基因变异与更高的体重指数 (BMI) 有关,但不会影响健康男性的运动相关脂肪或碳水化合物燃烧. 这表明,这种变异的肥胖风险可能源于食欲调节,而不是代谢灵活性.
科学领域:
- 遗传学和新陈代谢
- 运动生理学 运动生理学
背景情况:
- 黑色皮质素4受体 (MC4R) 基因在调节能量平衡和体重方面发挥着至关重要的作用.
- 在MC4R基因中的单核酸多态 (SNP),如rs17782313,与肥胖风险有关.
- 了解身体活动期间这些变异的代谢后果对于阐明肥胖机制很重要.
研究的目的:
- 为了研究MC4R rs17782313 (T>C) 多态化对基质氧化的影响,在健康的久坐不动的男性在分级运动期间.
- 确定这种基因变异是否影响关键的代谢反应,包括氧气消耗 (VO2) 和呼吸系数 (RQ).
- 为了将基因型与体重指数 (BMI) 相对应,并评估对代谢灵活性的潜在影响.
主要方法:
- 48名健康的久坐不动的男性 (年龄在20-30岁) 的基因定型,用于MC4Rrss17782313多态.
- 进行分级运动测试,同时进行呼吸气体分析,以测量VO2,RQ和基质氧化率 (脂肪和碳水化合物).
- 在C基因基因携带者 (风险基因基因) 和TT同胞体之间的代谢参数和BMI的比较.
主要成果:
- 在中等强度运动 (p > 0.05) 期间,在呼吸系数 (RQ),脂肪氧化百分比或碳水化合物氧化百分比方面,没有发现C基因携带者和TT同胞体之间的显著差异.
- 观察到体重指数 (BMI) 的显著差异,C-基因基因携带者与TT同胞相比,BMI值更高 (p < 0.05).
- MC4R rs17782313变体与脂肪增加有关,但与运动期间急性基质利用的改变无关.
结论:
- MC4R rs17782313多态性与更高的BMI有关,这表明它在脂肪性中发挥了作用.
- 这种特定变异似乎不会影响健康个体在急性炼期间的代谢灵活性或基质利用.
- MC4R rs17782313变体对肥胖风险的贡献可能主要是通过通过行为或神经内分泌途径对能量摄入的影响,而不是体力活动期间的代谢障碍.
相关概念视频
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...